MetaADEDB 2.0 @ LMMD
dexamethasone 21-phosphate
(PLCQGRYPOISRTQ-FCJDYXGNSA-L)
Structure
SMILES
O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@]2(F)[C@@H](O)C[C@]2([C@H]1C[C@H]([C@]2(O)C(=O)COP(=O)([O-])[O-])C)C)C.[Na+].[Na+]
Molecular Formula:
C22H28FNa2O8P
Molecular Weight:
516.405
Log P:
2.8891
Hydrogen Bond Acceptor:
8
Hydrogen Bond Donor:
2
TPSA:
156.83
CAS Number(s):
2392-39-4; 55203-24-2
Synonym(s)
1.
dexamethasone 21-phosphate
2.
Decadron phosphate
3.
Solu- Decadron
4.
Spersadex
5.
Spersadox
6.
dexamethasone 21-phosphate, (6alpha,11beta,16alpha)-isomer
7.
dexamethasone 21-phosphate, copper (+2) salt (2:3), (11beta,16alpha)-isomer
8.
dexamethasone 21-phosphate, disodium salt, (11beta,16alpha)-isomer
9.
dexamethasone 21-phosphate, disodium salt, (6alpha,11beta,16alpha)-isomer
10.
dexamethasone 21-phosphate, monosodium salt, (11beta,16alpha)-isomer
11.
dexamethasone 21-phosphate, sodium salt, (11beta,16alpha)-isomer
12.
dexamethasone phosphate
13.
dexamethasone phosphate disodium salt
14.
dexamethasone sodium phosphate
15.
dexamethasonedisodium phosphate
External Link(s)
MeSHC004180
PubChem Compound45357793
16961
ChEBI4462
CHEMBLCHEMBL2021430
KEGGcpd:C08175
dr:D00975
Therapeutic Target DatabaseD0NA8U
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Injection site painFAERS: 40US FAERS
2PainFAERS: 23US FAERS
3Injection site erythemaFAERS: 14US FAERS
4Intentional product use issueFAERS: 11US FAERS
5Product quality issueFAERS: 9US FAERS
6UrticariaFAERS: 9US FAERS
7HypersensitivityFAERS: 8US FAERS
8HeadacheFAERS: 7US FAERS
9Procedural nauseaFAERS: 6US FAERS
10Procedural vomitingFAERS: 6US FAERS
11DizzinessFAERS: 5US FAERS
12Drug ineffectiveFAERS: 5US FAERS
13ErythemaFAERS: 5OFFSIDES
US FAERS
14Injection site warmthFAERS: 5US FAERS
15Product use issueFAERS: 5US FAERS
16Tympanic Membrane PerforationFAERS: 5US FAERS
17AnosmiaFAERS: 4US FAERS
18ArthralgiaFAERS: 4US FAERS
19Incorrect route of drug administrationFAERS: 4US FAERS
20LethargyFAERS: 4US FAERS
21Mental status changesFAERS: 4US FAERS
22Nasal discomfortFAERS: 4US FAERS
23PruritusFAERS: 4US FAERS
24PurulenceFAERS: 4US FAERS
25Skin lesionFAERS: 4US FAERS
26VIIth nerve paralysisFAERS: 4US FAERS
27Back PainFAERS: 3US FAERS
28Central nervous system lesionFAERS: 3US FAERS
29DiscomfortFAERS: 3US FAERS
30Disease recurrenceFAERS: 3US FAERS
31DysarthriaFAERS: 3US FAERS
32Eye painFAERS: 3US FAERS
33HypotensionFAERS: 3US FAERS
34Injection Site ReactionFAERS: 3US FAERS
35Maternal exposure during pregnancyFAERS: 3US FAERS
36Product contaminationFAERS: 3US FAERS
37Product use in unapproved indicationFAERS: 3US FAERS
38Respiratory FailureFAERS: 3US FAERS
39Wound InfectionFAERS: 3US FAERS
40Anaphylactic shockFAERS: 2US FAERS
41AstheniaFAERS: 2US FAERS
42Blood glucose increasedFAERS: 2US FAERS
43Burning sensationFAERS: 2US FAERS
44CalcinosisFAERS: 2US FAERS
45Cerebrovascular accidentFAERS: 2US FAERS
46Chest PainFAERS: 2US FAERS
47Deafness NeurosensoryFAERS: 2US FAERS
48Depressed Level of ConsciousnessFAERS: 2US FAERS
49Expired product administeredFAERS: 2US FAERS
50ExtravasationFAERS: 2US FAERS
51Fat necrosisFAERS: 2US FAERS
52Feeling abnormalFAERS: 2US FAERS
53GastroenteritisFAERS: 2OFFSIDES
US FAERS
54Grip strength decreasedFAERS: 2US FAERS
55Growth retardationFAERS: 2US FAERS
56InfectionFAERS: 2US FAERS
57Injection site infectionFAERS: 2US FAERS
58Injection site inflammationFAERS: 2US FAERS
59Injection site pruritusFAERS: 2US FAERS
60Injection site scabFAERS: 2US FAERS
61Injection site ulcerFAERS: 2US FAERS
62Lung AbscessFAERS: 2OFFSIDES
US FAERS
63Medication ErrorFAERS: 2US FAERS
64Muscle RigidityFAERS: 2US FAERS
65MyopathyFAERS: 2US FAERS
66NauseaFAERS: 2US FAERS
67No adverse eventFAERS: 2US FAERS
68PalpitationsFAERS: 2US FAERS
69Posterior reversible encephalopathy syndromeFAERS: 2US FAERS
70Respiratory distressFAERS: 2US FAERS
71Soft Tissue InfectionFAERS: 2US FAERS
72SwellingFAERS: 2US FAERS
73SyncopeFAERS: 2US FAERS
74ThrombosisFAERS: 2US FAERS
75Vascular occlusionFAERS: 2US FAERS
76Visual ImpairmentFAERS: 2US FAERS
77VomitingFAERS: 2US FAERS
78Wheelchair userFAERS: 2US FAERS
79AbasiaFAERS: 1US FAERS
80Abdominal PainFAERS: 1US FAERS
81AbscessFAERS: 1US FAERS
82Accidental exposure to productFAERS: 1US FAERS
83Accidental exposure to product packagingFAERS: 1US FAERS
84Acute Coronary SyndromeFAERS: 1US FAERS
85Administration site erythemaFAERS: 1US FAERS
86Adrenogenital SyndromeFAERS: 1US FAERS
87Alanine Aminotransferase IncreasedFAERS: 1OFFSIDES
US FAERS
88Anaphylactoid ReactionFAERS: 1US FAERS
89AngerFAERS: 1US FAERS
90AnxietyFAERS: 1US FAERS
91Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
92AsthmaFAERS: 1OFFSIDES
US FAERS
93Blood chloride increasedFAERS: 1US FAERS
94Blood phosphorus increasedFAERS: 1US FAERS
95Blood urea nitrogen/creatinine ratio increasedFAERS: 1US FAERS
96Body fat disorderFAERS: 1US FAERS
97Bone infarctionFAERS: 1OFFSIDES
US FAERS
98Brain AbscessFAERS: 1US FAERS
99Breakthrough PainFAERS: 1US FAERS
100Carbon dioxide decreasedFAERS: 1US FAERS
101Cardiac HypertrophyFAERS: 1US FAERS
102CatatoniaFAERS: 1US FAERS
103CellulitisFAERS: 1US FAERS
104Cerebral InfarctionFAERS: 1US FAERS
105Choking sensationFAERS: 1US FAERS
106Corneal defectFAERS: 1US FAERS
107Corneal graft rejectionFAERS: 1OFFSIDES
US FAERS
108CryingFAERS: 1US FAERS
109Deep Vein ThrombosisFAERS: 1US FAERS
110DehydrationFAERS: 1US FAERS
111DeliriumFAERS: 1US FAERS
112Device difficult to useFAERS: 1US FAERS
113Diabetes InsipidusFAERS: 1US FAERS
114Diabetes MellitusFAERS: 1US FAERS
115Diabetic KetoacidosisFAERS: 1US FAERS
116Disseminated Intravascular CoagulationFAERS: 1OFFSIDES
US FAERS
117Drug abuseFAERS: 1US FAERS
118Drug dispensing errorFAERS: 1US FAERS
119Drug exposure during pregnancyFAERS: 1US FAERS
120Drug label confusionFAERS: 1US FAERS
121Duodenal perforationFAERS: 1US FAERS
122EscharFAERS: 1US FAERS
123ExcoriationFAERS: 1US FAERS
124ExophthalmosFAERS: 1US FAERS
125Expired drug administeredFAERS: 1US FAERS
126Eye irritationFAERS: 1US FAERS
127FlushingFAERS: 1US FAERS
128Food aversionFAERS: 1US FAERS
129Fungal abscess central nervous systemFAERS: 1US FAERS
130Gastric ulcerFAERS: 1US FAERS
131GranulomaFAERS: 1OFFSIDES
US FAERS
132Hepatitis CFAERS: 1US FAERS
133HyperkeratosisFAERS: 1US FAERS
134Hypertrophic CardiomyopathyFAERS: 1US FAERS
135HypervigilanceFAERS: 1US FAERS
136Immediate post-injection reactionFAERS: 1US FAERS
137Impaired work abilityFAERS: 1US FAERS
138Incorrect dose administeredFAERS: 1US FAERS
139Incorrect route of product administrationFAERS: 1US FAERS
140Increased upper airway secretionFAERS: 1US FAERS
141IndurationFAERS: 1US FAERS
142Infection in an immunocompromised hostFAERS: 1US FAERS
143Infusion site discomfortFAERS: 1US FAERS
144Injection site dischargeFAERS: 1US FAERS
145Injection site injuryFAERS: 1US FAERS
146Injection site joint swellingFAERS: 1US FAERS
147Injection site scarFAERS: 1US FAERS
148Injection site thrombosisFAERS: 1US FAERS
149Insulin ResistanceFAERS: 1US FAERS
150Intentional self-injuryFAERS: 1US FAERS
151Joint abscessFAERS: 1US FAERS
152Joint swellingFAERS: 1US FAERS
153Lip swellingFAERS: 1US FAERS
154Local reactionFAERS: 1US FAERS
155LymphadenopathyFAERS: 1US FAERS
156Memory impairmentFAERS: 1US FAERS
157Mood swingsFAERS: 1US FAERS
158MucormycosisFAERS: 1US FAERS
159Musculoskeletal discomfortFAERS: 1US FAERS
160MyalgiaFAERS: 1US FAERS
161Myocardial InfarctionFAERS: 1US FAERS
162MyocarditisFAERS: 1US FAERS
163MyositisFAERS: 1US FAERS
164NervousnessFAERS: 1US FAERS
165NeuralgiaFAERS: 1US FAERS
166Neuroleptic Malignant SyndromeFAERS: 1US FAERS
167Ocular discomfortFAERS: 1US FAERS
168Oropharyngeal painFAERS: 1OFFSIDES
US FAERS
169Otitis MediaFAERS: 1US FAERS
170Packaging design issueFAERS: 1US FAERS
171PapuleFAERS: 1US FAERS
172Pericardial effusionFAERS: 1US FAERS
173Perineal painFAERS: 1US FAERS
174Peripheral swellingFAERS: 1US FAERS
175PolydipsiaFAERS: 1US FAERS
176PresyncopeFAERS: 1US FAERS
177Product contamination physicalFAERS: 1US FAERS
178Product label confusionFAERS: 1US FAERS
179Product packaging confusionFAERS: 1US FAERS
180Pulmonary EmbolismFAERS: 1US FAERS
181Respiratory tract congestionFAERS: 1US FAERS
182Retinal Vascular DisorderFAERS: 1US FAERS
183Scedosporium infectionFAERS: 1US FAERS
184ScleritisFAERS: 1US FAERS
185Secretion dischargeFAERS: 1US FAERS
186Selective MutismFAERS: 1US FAERS
187SepsisFAERS: 1US FAERS
188Simplex virus test positiveFAERS: 1US FAERS
189Skin irritationFAERS: 1US FAERS
190SomnolenceFAERS: 1US FAERS
191StridorFAERS: 1OFFSIDES
US FAERS
192StrongyloidiasisFAERS: 1US FAERS
193TachycardiaFAERS: 1US FAERS
194Therapeutic product ineffectiveFAERS: 1US FAERS
195ThirstFAERS: 1US FAERS
196Throat irritationFAERS: 1US FAERS
197TremorFAERS: 1US FAERS
198Unevaluable eventFAERS: 1US FAERS
199Varicella Zoster Virus InfectionFAERS: 1US FAERS
200Wrong technique in product usage processFAERS: 1US FAERS
201AgeusiaOFFSIDES
202AgnosiaOFFSIDES
203Anal erosionOFFSIDES
204AnorexiaOFFSIDES
205Anticonvulsant drug level below therapeuticOFFSIDES
206ApathyOFFSIDES
207AscitesOFFSIDES
208AutomatismOFFSIDES
209Bilirubin conjugated increasedOFFSIDES
210Blood amylase increasedOFFSIDES
211Blood blisterOFFSIDES
212Blood creatinine increasedOFFSIDES
213Blood lactate dehydrogenase increasedOFFSIDES
214Blood urea increasedOFFSIDES
215Blood uric acidOFFSIDES
216Blood zinc decreasedOFFSIDES
217Bronchoalveolar LavageOFFSIDES
218Cancer PainOFFSIDES
219CataractOFFSIDES
220Catheter related complicationOFFSIDES
221Catheter site erythemaOFFSIDES
222Cerebellar infarctionOFFSIDES
223CholecystitisOFFSIDES
224Corneal erosionOFFSIDES
225Culture positiveOFFSIDES
226DiarrheaOFFSIDES
227DystoniaOFFSIDES
228EczemaOFFSIDES
229Electrocardiogram ST-T segment depressionOFFSIDES
230Epidural AbscessOFFSIDES
231Erythema MultiformeOFFSIDES
232Febrile NeutropeniaOFFSIDES
233Genital discomfortOFFSIDES
234Genital erosionOFFSIDES
235Genital rashOFFSIDES
236Glaucoma surgeryOFFSIDES
237GlaucomaOFFSIDES
238GlioblastomaOFFSIDES
239GlobulinuriaOFFSIDES
240GranulocytosisOFFSIDES
241ImmunosuppressionOFFSIDES
242IncontinenceOFFSIDES
243Intestinal ObstructionOFFSIDES
244Intestinal PerforationOFFSIDES
245KeratopathyOFFSIDES
246Leukopenia neonatalOFFSIDES
247Lymphangiosis carcinomatosaOFFSIDES
248Lymphocyte count decreasedOFFSIDES
249Malignant neoplasm progressionOFFSIDES
250Metastatic NeoplasmOFFSIDES
251MyotoniaOFFSIDES
252NeuroblastomaOFFSIDES
253Neutrophil count decreasedOFFSIDES
254Oral Cavity FistulaOFFSIDES
255Oral mucosal exfoliationOFFSIDES
256PallorOFFSIDES
257Palmar erythemaOFFSIDES
258PneumobiliaOFFSIDES
259Postoperative wound complicationOFFSIDES
260Pre-EclampsiaOFFSIDES
261ProctitisOFFSIDES
262RalesOFFSIDES
263Retinal Artery OcclusionOFFSIDES
264Retinal Vein OcclusionOFFSIDES
265Retinal vascular occlusionOFFSIDES
266RhinorrheaOFFSIDES
267ScleremaOFFSIDES
268Septic embolusOFFSIDES
269SequestrectomyOFFSIDES
270Stevens-Johnson SyndromeOFFSIDES
271Sudden deathOFFSIDES
272Treatment related secondary malignancyOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.